Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival Aflibercept for Pseudophakic CME
NCT03396861Phase 1Terminated
- Sponsor
- Tufts Medical Center
- Start
- Feb 2019
- Primary completion
- Aug 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aflibercept in pseudophakic cystoid macular edema (PCME), sponsored by Tufts Medical Center. Primary endpoint: Adverse Events at Month 2. Started Feb 2019; status: terminated.
02
Drugs
aflibercept
03
Conditions
pseudophakic cystoid macular edema (PCME)
Beyond the preview
Go deeper on NCT03396861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396861.